Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Conditions:   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Undifferentiated CarcinomaInterventions:   Drug: Azacitidine;   Drug: Vorinostat;   Other: Pharmacological Study;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials